anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease (CKD) patients have very low physical function and high rates of cardiovascular disease (CVD) mortality. The objective of the proposed research is to evaluate the effects of dietary supplementation with a pomegranate extract, that contains high amounts of antioxidants, on physical function and CVD risk. Patients with moderate to severe chronic kidney disease that are NOT yet on dialysis tend to have significantly reduced risk factors for cardiovascular disease (and other disorders) compared to dialysis patients. This includes significantly reduced systemic markers of oxidative stress and inflammation. As a result, therapies designed to reduce the risk of CKD co-morbidities may differ significantly in dialysis and pre-dialysis patients. For example, dialysis patients are recommended to INCREASE their intake of dietary protein, while pre-dialysis patients are recommended to DECREASE their protein intake, due to differences in the pathophysiology of the two conditions. The investigators have decided to recruit pre-dialysis patients in addition to dialysis patients in this study because the investigators believe this will help us determine if the efficacy of pomegranate differs between patients with different stages of CKD.

CKD patients will be recruited under 2 phases: CKD patients not receiving dialysis treatment (pre-dialysis patients) will be recruited in the first phase. This will include patients with CKD stage 3-5 that are not yet on dialysis. In the second phase, only CKD patients on dialysis treatment will be recruited. To address these questions, CKD patients will be randomized to the following groups for 12 months: 1) no POM supplementation/control (CON), and 2) oral supplementation with purified pomegranate extract (POM). Patients in the POM group will ingest a 1000 milligram capsule of POM extract, 7 days per week. Patients in the CON group will receive a placebo capsule using the same protocol.

On three occasions, at baseline, 6, and 12 months, each subject will have blood collected to measure plasma markers of oxidative stress (TBARS, lipid peroxides), blood lipid levels, and glucose and insulin levels. Arterial and cardiac structure and function will be measured by vascular ultrasound and echocardiogram, respectively. A 24-hour dietary recall will be used to assess the intake of nutrients. Leg strength will be measured on a resistance exercise machine. Bone density and body composition will be evaluated using dual energy x-ray absorptiometry (DXA). Pre-dialysis subjects will undergo a maximal exercise test to assess their cardiorespiratory fitness level. In dialysis patients, instead of a maximal exercise test, physical function will be measured by a 6-item functional fitness assessment and a 10-meter walk test.
1. Use of L. casei strain for preparing a composition for oral administration to effect T-cells proliferation specific to pathogenic micro-organisms to enhance specific systemic immune response to pathogenic micro-organisms. 2. Use according to claim 1, characterized in that said pathogenic micro-organisms is a pathogen of respiratory tract. 3. Use according to claim 1 or 2, characterized in that said pathogenic micro-organisms is a virus selected from rhinovirus, respiratory-syncitial virus and myxovirus. 4. Use according to claim 1, characterized in that said virus an influenza virus. 5. Use according to any one of claims 1-4, characterized in that said L. casei is CNCM1-1518 strain. 6. Use according to any one of claims 1-5, characterized in that composition is in the form of a food or food supplement. 7. Use according to any one of claims 1-6, characterized in that composition is in the form of sourly-fermented product.
BACKGROUND: Systemic inflammation causes several organ damage by activating the intracellular signaling mechanisms. Heart and aorta tissues are the structures mostly affected by this situation. By examining underlying processes, this study sought to determine whether cannabidiol (CBD) may have protective effects against the cardiovascular damage brought on by lipopolysaccharide (LPS).
MATERIALS AND METHODS: A total of 32 female rats were randomly allocated to one of four groups: control, lipopolysaccharide (LPS) (5 mg/kg, i.p., single dose), LPS + CBD (5 mg/kg, i.p., single dose), and CBD groups. The rats were killed six hours after receiving LPS, and tissues from the heart and aorta were taken. Histopathological and immunohistochemical analyzes were performed. Oxidative stress was evaluated biochemically by spectrophotometric method. Expression levels of genes were studied by RT-qPCR method.
RESULTS: Histopathological analysis of the LPS group showed moderate hyperemia, hemorrhages, edema, inflammation, and myocardial cell damage. There was a slight to moderate increase in Cox-1, G-CSF, and IL-3 immunoexpressions, along with enhanced expressions of IL-6, Hif1α, and STAT3 genes, and decreased expressions of eNOS genes. Additionally, there were increased levels of TOS and decreased TAS levels observed biochemically. CBD treatment effectively reversed and improved all of these observed changes.
CONCLUSIONS: CBD protects the heart and aorta against systemic inflammation through its antioxidant and anti-inflammatory activity via regulating IL-6, Hif1α, STAT3, and eNOS intracellular pathways.
PURPOSE:To readily obtain a high-quality and stable dehydrated medicine, by incorporating anhydrous maltose in a medicine, raw material therefor or processed intermediate material thereof, converting the water in the hydrous material into beta-maltose hydrous crystals and dehydrating the hydrous material. CONSTITUTION:For example, anhydrous maltose, particularly containing >=85w/w%, based on the solid material, maltose is incorporated in a medicine, e.g. nutriment, physiologically active material agent, germicide, etc., raw material therefor or processed intermediate material thereof to dehydrate the hydrous material. The anhydrous maltose is capable of converting water in various kinds of hydrous materials into beta-maltose hydrous crystals to substantially reduce the water therein and dehydrate the hydrous material. Crystalline anhydrous alpha-maltose, crysalline beta-maltose, amorphous anhydrous maltose, etc., may be preferred as the anhydrous maltose. The anhydrous maltose acts also as a stabilizer and is capable of producing a high-quality and stable dehydrated physiologically active material agent.
Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
Group A: Minimally trained operators for LVOT VTI measurement will be intensive care residents and medical students having done less than 20 transthoracic echocardiography (TTE). All untrained operators will benefit from a standardized preliminary minimal training to teach them how to obtain apical 5-chamber view and acquire LVOT VTI using pulsed-wave Doppler according to the guidelines of the American Society of Echocardiography.
Oral cavity wound healing occurs in an environment that sustains ongoing physical trauma and is rich in bacteria. Patients undergoing cleft palate repair have a high degree of wound healing complications, such as oronasal fistula (ONF) formation. Following hard palate injury, ONF was created that demonstrated little change in pro-regenerative monocytes LY6Clo monocytes; however, there were increased M2 macrophages observed. Delivery of FTY720 nanofiber scaffolds following hard palate injury prevented ONF formation, allowed complete wound healing and was associated with increased LY6Clo monocytes and pro-regenerative M2 macrophages. Evaluation of interleukin gene expression revealed reduction in pro-inflammatory IL1 and IL6 and increased expression of pro-regenerative IL10 with FTY720 nanofiber delivery. The ability of FTY720 scaffolds to increase LY6Clo monocytes, increase M2 macrophages and alter the interleukin expression during hard palate mucosal healing demonstrates the ability of a FTY720-based autotherapy to improve oral cavity wound healing.
Recently, hypoxic areas have been identified in water bodies of the Pampas region due to human activity. The objective of this work was to study the effect of low concentrations of dissolved oxygen (hypoxia) on the reproductive endocrine axis of a pampas fish (Odontesthes bonariensis). Groups of 8 males and 8 females were subjected to severe hypoxia (2-3 mg l-1) and normoxia (7-9 mg l-1) in 3000 l tanks by duplicate during the reproductive season (spring). After 21 days, 4 males and 4 females from each tank were sacrificed, and blood was drawn to measure estradiol (E2) and testosterone (T). The brain, pituitary gland and a portion of the gonads were extracted and processed to measure the expression of: gnrh1, cyp19a1b, fshβ, lhβ, fshr, lhcgr and cyp19a1a. From the second experimental week, no spawning was found in the hypoxic females, while at the end of the treatment period no male released sperm. Fish under hypoxic conditions showed signs of gonadal regression, reduction of GSI and plasma levels of sex steroids. Furthermore, the expression of gnrh1 in both sexes, cyp19a1b and fshr in males and only fshβ and cyp19a1a in females decreased in comparison with normoxic fish. After 40 days under normal conditions, signs of reproductive recovery were observed in the treated fish. The results obtained demonstrated that hypoxia generated an inhibition of some components of the pejerrey's reproductive endocrine axis, but the effect was reversible.
Obesity can decrease the lung function. The proposed mechanisms of reduced lung function in persons with obesity have been altered mechanical properties in the lung and chest wall, airway narrowing and increased respiratory resistance. The aim of this current study was to analyse the long-term results after gastric bypass surgery in patients with reduced lung function. The bariatric surgery observation study invited patients to a follow up 10 years after gastric bypass surgery. We compared the spirometry results before surgery to the spirometry 10 years after surgery. Thirty percent of 198 participants had reduced lung function before surgery. There was no significant relation between body mass index before surgery and lung function. Seventy-three percent of the participants with reduced lung function had normal lung function 10 years after surgery. There was no significant relation between the degree of weight loss and the improvement in lung function. Most participants with reduced lung function had normal lung function 10 years after gastric bypass surgery. There was no significant correlation between weight loss and improvement in lung function.
Acetylcysteine injection is available as a 20% solution (200 mg/mL) in 30 mL single-dose glass vials. Each single dose vial contains 6 g/30 mL (200 mg/mL) of acetylcysteine injection. Acetylcysteine injection is sterile and can be used for intravenous administration. It is available as follows:

Do not use previously opened vials for intravenous administration.

Note: The color of Acetylcysteine injection may turn from essentially colorless to a slight pink or purple once the stopper is punctured. The color change does not affect the quality of the product.

The stopper in the Acetylcysteine injection vial is formulated with a synthetic base-polymer and does not contain Natural Rubber Latex, Dry Natural Rubber, or blends of Natural Rubber.

Store unopened vials at controlled room temperature, 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]
This is a Stage 1 intervention development study. This study asks: "what behavioral strategies are needed to help socially disconnected caregivers with significant barriers to increasing connectedness?" Pilot 2 uses a mixed methods approach to adapt a brief behavioral intervention-Social Engage psychotherapy-for use with socially disconnected caregivers, which we call Engage Coaching for Caregivers. The ultimate goal is for Engage Coaching for Caregivers to be offered as a second step in a stepped care approach for caregivers who do not demonstrate an adequate response to a single-session psychoeducation plus resources intervention. Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months. This is a single-arm clinical trial with up to 30 participants. The study's primary objective is to discover the most useful strategies to promote social connectedness in the context of caregiving. Participants will complete up to 8 weekly individual Engage Coaching sessions via phone or Zoom. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and "barrier strategies" are added only if needed. Coaches and the PI will work together to devise caregiver specific barrier strategies as needed, such as brief communication skills coaching or education on behavioral issues in dementia. The development and piloting of these new caregiver specific barrier strategies is a key objective of this pilot study. During the data analysis phase, we will conduct qualitative analyses from participants on which of these strategies were most useful and combined with experiences from therapists, we will adapt the therapy manual to include the most useful strategies, for testing in a subsequent Stage II efficacy trial.
IBD patients attending the Stanford Inflammatory Bowel Disease (IBD) clinic and age-matched healthy controls are screened for eligibility. Informed consent is obtained for eligible subjects. An anonymous self-administered questionnaire is administered to assess risk factors for HPV. For IBD patients, information regarding IBD diagnosis and treatment is obtained.

An anal pap smear is performed at the time of a clinic visit or at the time of an already scheduled colonoscopy. Samples are collected and processed at Stanford pathology where a blinded pathologist reads all specimens. Human Papillomavirus (HPV) DNA testing is performed on all specimens. All patients with anal squamous intraepithelial lesion (ASIL) are referred to a colorectal surgeon for further recommendations or treatment, which includes a high-resolution anoscopy.
Participants will undergo endothelial keratoplasty procedure. Participants will be followed up for up to 1 year.
PURPOSE:To easily obtain in high safety the title material extremely mild in digestion and absorption, having taste and mouth feeling similar to those of conventional starch by bringing a fatty acid compound, in the presence of a solvent, into contact with a starch of specified amylose content. CONSTITUTION:(A) 100 pts.wt. of a starch containing 25-60wt.% of amylose is brought, in the presence of (B) pref. 10-100 pts.wt. of a solvent (e.g. water, an alcohol), into contact with (C) pref. 0.5-20 pts.wt. of a fatty acid compound (pref. an amphiphatic substance, esp. fatty acid ester), thus giving the objective material >=10% in the amylose occupancy rate in the component A by the component B.
PURPOSE:The titled antagonistic agent, containing melatonin of pineal body hormone as an active constituent, capable of antagonizing the action of glucocorticoid, and useful for preventing and treating an invasion state caused by mental factors, hemorrhage, external wounds, infection, etc. CONSTITUTION:A glucocorticoid antagonistic agent containing melatonin; N-[2- (5-methoxyindol-3-yl)ethyl] acetamide of the formula. If invasion is excessive, adrenocortical function is abnormally exacerbated to cause excess secretion of the glucocorticoid and incur remarkable consumption of physical strength. The melatonin is found to be capable of controlling the excess state of the glucocorticoid and has anti-invasion action and useful for preventing and treating the invasion state caused by delivery, external wounds, surgical operation, etc. The dose thereof is 1-500mg/day for oral administration and 1-30mg/day for intravenous injection. The above-mentioned agent is safe with low toxicity.
The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NC Ca-ATP  channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NC Ca-ATP  channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.
A polymerization apparatus according to an embodiment of the present invention includes: a light irradiator; and a polymerization vessel. The light irradiator includes a first casing and a light source assembly. The first casing includes a light source chamber defined by cylindrical side walls, a ceiling, and a floor including a light-transmissive window member. The light source assembly includes a base having a light-emitting surface on which a plurality of light-emitting diodes is disposed in a predetermined pattern and a heat-dissipating surface to which a heat sink is joined, and the light source assembly is disposed within the light source chamber so that the light-emitting surface faces the light-transmissive window member. The polymerization vessel includes a polymerization cup and a second casing. The polymerization cup has a frustoconical or substantially frustoconical shape that opens upward and increases in diameter upward, and is capable of housing an object therein. The second casing is a bottomed cylindrical or box-shaped casing having an opening at the apex thereof, the polymerization cup being attachably/detachably housed in the second casing via the opening. In this polymerization apparatus, light that has been emitted by the plurality of light-emitting diodes of the light irradiator and has passed through the light-transmissive window member is applied to the inside of the polymerization cup of the polymerization vessel.
At the screening visit, the study will be explained, and the participant will have the opportunity to ask questions. If the participant decides to enroll, they will have to read, sign and date this Informed Consent Document. The study staff will take the participants pertinent medical history to evaluate eligibility. The participant will be asked about the kind of skin products they are using as well as about use of PPE. Visit 2 activities may be performed at the Screening visit.

Participants will return to the study site one (1) week later and 28-days later to have Photographs, Skin Function Testing, and Laboratory Testing performed. The participant will be asked to avoid applying any skin products (except make-up) to the skin for the following week and for the duration of the study.
The invention discloses a bone strengthening collateral dredging powder. According to the specific scheme, the bone strengthening collateral dredging powder is prepared from 2-4 centipedes, 5-15 g of whole worms, 5-20 g of ground beetles and 5-20 g of coptis chinensis. According to the eating method of the bone strengthening collateral dredging powder, the medicinal materials are ground into powder after being matched proportionally; eggs are beaten, a proper amount of white sugar is added, and egg flowers are obtained through steaming; a user takes the egg flowers together with 2-3 g of the matched ground powdery traditional Chinese medicine orally every night. The bone strengthening collateral dredging powder is forbidden to be adopted with other medicines with the similar medicine effect. The bone strengthening collateral dredging powder is not suitable for being taken excessively, centipedes and whole worms have a certain negative effect on the liver disease, coptis chinensis and ground beetles are beneficial to the liver disease, and the liver protection effect is achieved. The bone strengthening collateral dredging powder is contraindicated in pregnancy. The bone strengthening collateral dredging powder is simple in component, scientific in medicine compatibility, good in curative effect and free of side effects and becomes effectively rapidly. The bone strengthening collateral dredging powder has the better effect on pain, paralysis and mobility difficulty caused by poliomyelitis, facial paralysis, epilepsia, spasm, tuberculosis and various bone diseases and common bone diseases such as rheumatism, rheumatoid, gout and osteoproliferation.
This is identical to the standing condition, but the breaks in sitting time will be punctuated with 5 minute bouts of light-intensity treadmill walking (equivalent to around 4.0km•h-1) rather than standing. In total, individuals will accumulate 12 bouts (60 minutes) of light-intensity activity throughout the test period. The light-intensity walking activity undertaken here replicates the low-grade ambulatory activity associated with everyday life.
PURPOSE:A hepatic disorder ameliorant that contains pantethine-S-sulfonic acid or its salt as an active ingredient, thus showing remarkable effect of inhibiting the formation of peroxidized lipid in serum. CONSTITUTION:The objective ameliorant contains pantethine-S-sulfonate or its salt and an alkali metal or alkaline earth metal salt as active ingredients. The resultant product is a white and crystalline powder, tastes not bitter and shows high effect of inhibiting the formation of peroxidized lipid in serum. It can be given orally or parenterally and its dose is preferably 100-1,000mg a day, usually 300-600mg a day. Pantethine-S-slufonic acid is isolated from naturally- occurring carrots or prepared advantageously from D-pantothenic acid and 2- aminoethanethiol sulfate. The resultant preparation is excellent in stability availability and preparation manfacturing.